After years of flying (mostly) under the radar in the legacy media, Gilead’s dirty tricks have made the New York Times, in a piece written by Rebecca Robbins and Sheryl Gay Stolberg.
May Gilead and its crooked allies be brought to justice!
Gilead's Truvada is a very bad drug that had deservedly fallen out of favor.
Gilead's Veklury/remdesivir is much worse -- it kills in just 10 days -- this deadly drug still is, or was for the past 3 years, the inpatient hospital standard of care for "Covid" under the (Doesn't) Cares Act legislation, which provides HUGE financial incentives to hospitals to use remdesivir even as it kills the patients by shutting down their kidneys.
There is more to the DESCOVY and TRUVADA discussion than it appears, apart from the fact that they are supposed to treat HIV and not AIDS.
DESCOVY contains the same active substances as Truvada, Tenofovir and Emtricitabin, though Tenofovir in a different formulation. DESCOVY, the latest generation of antiretroviral "therapy" (ART), contains 9x less tenofovir by molecular weight than its predecessor TRUVADA(!)
Both, DESCOVY and TRUVADA, are also used for so-called prophylaxis. The example DESCOVY and TRUVADA documents the dosage dependency(!) of the damages caused by the "therapy". The two formulations in tablets with 300 mg Tenofovir Disoproxil Fumarat (TDF, included in Truvada) and tablets containing 25 mg Tenofovir Alafenamide (TAF, included in Descovy) correspond to a 9-fold dosage reduction of Tenofovir based on molecular weight.
• „Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)”, Gilead Sciences, 2016 – 2020, https://clinicaltrials.gov/ct2/show/NCT02842086
Lo and behold, a significant improvement in kidney values and bone mineral density (BMD) is observed during prophylaxis in healthy(!) people who have switched from TRUVADA to DESCOVY, cf.
• „Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP”, Conference Reports for NATAP, IDWeek October 3 -7, 2018, San Francisco, CA, http://www.natap.org/2019/IDWeek/IDWeek_61.htm
“Improvements were statistically significant as early as Week 4 of the trial. At Week 48, eGFRCG increased by 3.9 mL/min from baseline for those randomized to F/TAF and decreased by 0.6 mL/min in those who continued to receive F/TDF (p<0.001).”
“Participants who were randomized to switch to F/TAF experienced statistically significant improvements in BMD of the hip and spine compared with those randomized to continue F/TDF. In addition, participants taking F/TAF for PrEP were significantly less likely to develop osteopenia of the spine.”
Previous data on dose dependent damages are practically non-existent, because modern medicine has proceeded since the mid 1980s according to the principle "hit hard and early". There are no safety studies for the putative antiretroviral substances. None of these substances would pass a safety test. And this, according to the unproven theory, to protect people from a virus that is supposed to cause symptoms 20 years after the infection (slow virus hypothesis).
HIV has nothing to do with the AID Syndrome, the collection of around 30 well know old diseases, that appeared in the 1980s for the first time in severely drug dependent and without any new virus severe sick populations of homosexuals, after years of drug and antibiotics abuse, years of malnutrition and multiple infections with sexually transmitted diseases. There is no relation between a positive HIV test and any symptoms after 20 years (slow virus hypothesis).
HIV doctors are convinced that there's a syndrome of gradual CD4 depletion associated with a positive HIV antigen test as well as with a PCR-detectable 'viral load' test, because this is what they see in otherwise asymptomatic - generally healthy - clinic patients. Moreover, the administration to such patients of the so-called ART compounds reverses the trends of CD4 depletion and rising 'viral loads', and this is why it's hard to shake them away from the virus hypothesis. What do you think is really going on with the nucleoside analogues and the dynamics of the differential T-cell count?
Ironically, the same doctors prescribing Truvada or Descovy as 'PReP' ART's - which will most likely be taken intermittently at best - are advising their HIV patents to avoid any discontinuations in the daily regularity of taking these same ART compounds so as to forestall the development of drug-resistant mutants of the 'the virus'. What do you suppose is really going on?
Thank you for your reporting! All the while the mainstream media has not been reporting on the dangers of PrEP, the industry has grown making it easier and easier to access these harmful meds. Here is just one of the many new companies focusing on getting this stuff into bodies via telemedicine and doorstep delivery.
Bittersweet, I imagine, to see your excellent reporting finally being corroborated by the Times, but terribly frustrating, too. Sheryl Gay Stolberg is my favorite of all NYTimes science writers (admittedly not a group I have much admiration for but she is nevertheless better than the rest). I'm not surprised to see her name on the story. It would have been nice had she at least come to you for a quote.
May Gilead and its crooked allies be brought to justice!
Gilead's Truvada is a very bad drug that had deservedly fallen out of favor.
Gilead's Veklury/remdesivir is much worse -- it kills in just 10 days -- this deadly drug still is, or was for the past 3 years, the inpatient hospital standard of care for "Covid" under the (Doesn't) Cares Act legislation, which provides HUGE financial incentives to hospitals to use remdesivir even as it kills the patients by shutting down their kidneys.
Unfortunately -- I'd say CRIMINALLY -- The FDA just approved remdesivir for use in patients with kidney disease. https://sagehana.substack.com/p/the-new-world-order-op-in-six-minutes/comment/21147216
This = financially incentivized murder of Covid patients and now kidney patients.
Nothing matters ... nothing matters! Sad, sad, sad. EVIL, EVIL, EVIL!!!!!!!!!!!!!!!!
There is more to the DESCOVY and TRUVADA discussion than it appears, apart from the fact that they are supposed to treat HIV and not AIDS.
DESCOVY contains the same active substances as Truvada, Tenofovir and Emtricitabin, though Tenofovir in a different formulation. DESCOVY, the latest generation of antiretroviral "therapy" (ART), contains 9x less tenofovir by molecular weight than its predecessor TRUVADA(!)
Both, DESCOVY and TRUVADA, are also used for so-called prophylaxis. The example DESCOVY and TRUVADA documents the dosage dependency(!) of the damages caused by the "therapy". The two formulations in tablets with 300 mg Tenofovir Disoproxil Fumarat (TDF, included in Truvada) and tablets containing 25 mg Tenofovir Alafenamide (TAF, included in Descovy) correspond to a 9-fold dosage reduction of Tenofovir based on molecular weight.
• „Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)”, Gilead Sciences, 2016 – 2020, https://clinicaltrials.gov/ct2/show/NCT02842086
Lo and behold, a significant improvement in kidney values and bone mineral density (BMD) is observed during prophylaxis in healthy(!) people who have switched from TRUVADA to DESCOVY, cf.
• „Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP”, Conference Reports for NATAP, IDWeek October 3 -7, 2018, San Francisco, CA, http://www.natap.org/2019/IDWeek/IDWeek_61.htm
“Improvements were statistically significant as early as Week 4 of the trial. At Week 48, eGFRCG increased by 3.9 mL/min from baseline for those randomized to F/TAF and decreased by 0.6 mL/min in those who continued to receive F/TDF (p<0.001).”
“Participants who were randomized to switch to F/TAF experienced statistically significant improvements in BMD of the hip and spine compared with those randomized to continue F/TDF. In addition, participants taking F/TAF for PrEP were significantly less likely to develop osteopenia of the spine.”
Previous data on dose dependent damages are practically non-existent, because modern medicine has proceeded since the mid 1980s according to the principle "hit hard and early". There are no safety studies for the putative antiretroviral substances. None of these substances would pass a safety test. And this, according to the unproven theory, to protect people from a virus that is supposed to cause symptoms 20 years after the infection (slow virus hypothesis).
HIV has nothing to do with the AID Syndrome, the collection of around 30 well know old diseases, that appeared in the 1980s for the first time in severely drug dependent and without any new virus severe sick populations of homosexuals, after years of drug and antibiotics abuse, years of malnutrition and multiple infections with sexually transmitted diseases. There is no relation between a positive HIV test and any symptoms after 20 years (slow virus hypothesis).
HIV doctors are convinced that there's a syndrome of gradual CD4 depletion associated with a positive HIV antigen test as well as with a PCR-detectable 'viral load' test, because this is what they see in otherwise asymptomatic - generally healthy - clinic patients. Moreover, the administration to such patients of the so-called ART compounds reverses the trends of CD4 depletion and rising 'viral loads', and this is why it's hard to shake them away from the virus hypothesis. What do you think is really going on with the nucleoside analogues and the dynamics of the differential T-cell count?
Ironically, the same doctors prescribing Truvada or Descovy as 'PReP' ART's - which will most likely be taken intermittently at best - are advising their HIV patents to avoid any discontinuations in the daily regularity of taking these same ART compounds so as to forestall the development of drug-resistant mutants of the 'the virus'. What do you suppose is really going on?
Thank you for your reporting! All the while the mainstream media has not been reporting on the dangers of PrEP, the industry has grown making it easier and easier to access these harmful meds. Here is just one of the many new companies focusing on getting this stuff into bodies via telemedicine and doorstep delivery.
https://www.prep2me.com/
Bittersweet, I imagine, to see your excellent reporting finally being corroborated by the Times, but terribly frustrating, too. Sheryl Gay Stolberg is my favorite of all NYTimes science writers (admittedly not a group I have much admiration for but she is nevertheless better than the rest). I'm not surprised to see her name on the story. It would have been nice had she at least come to you for a quote.